AusBiotech

AusBiotech was pleased to be invited to participate in a HealthTech Roundtable and Business Luncheon with the Hong Kong Government’s Financial Secretary, Mr Paul Chan, and members to discuss growth opportunities for Australian biotech in Hong Kong and Asia.

CSL Limited (ASX:CSL) has announced the sale of its Wuhan Zhong Yuan Rui De Biologicals Products (Ruide) plasma collection and fractionation operations to Chengdu Rongsheng Pharmaceutical for USD$185 million in cash proceeds.

Noxopharm (ASX:NOX) has announced progress on its Chroma technology platform, encouraging early drug leads with anticancer activity for glioblastoma and leukaemia.

Lumos Diagnostics (ASX:LDX) has launched an equity offering that will raise up to approximately $10 million through a pro-rata accelerated non-renounceable entitlement offer.

Opthea (ASX:OPT) has announced executive leadership changes in finance and commercial and senior hires for biometrics, clinical operations and market access.

The workshop, in partnership with Australia’s Chief Scientist Dr Cathy Foley, aims to accelerate the take-up of and build the demand for quantum technologies in Australia’s health sciences sector.

Percheron Therapeutics (ASX:PER) says preclinical data for its lead program, avicursen (ATL1102), further validates its pharmacological activity as an anti-inflammatory agent.

MTPConnect has announced a new $28.5 million investment program supported by CSL and Roche Diagnostics for innovative small—and medium-sized enterprises developing innovative products targeting cardiovascular disease and diabetes.

Australian company Emyria (ASX:EMD) has announced interim clinical results from an analysis of its MDMA-assisted therapy for post-traumatic stress disorder program, which commenced in October 2023.

Race Oncology (ASX:RAC) has announced that the first phase of the board renewal process, which commenced in 2023, is now complete with a newly appointed board.

The biggest programme to date, the AusBiotech 2024 National Conference features over 60 engaging sessions and more than 200 speakers in Melbourne from 30 October to 1 November.

AusBiotech is delighted to welcome two new senior leaders to its team with both roles focused on elevating and amplifying the voice of our members as we work to accelerate the growth of Australia’s biotech and medtech industry.